Abstract
This chapter covers basic concepts pertaining to designing drug-drug interaction studies and interpreting results. Planning a drug-drug interaction study should encompass a statement of the rationale for doing the study. The basic design involves a two-period randomized crossover study with two treatment sequences; however, more complex and alternative study designs are discussed. Considerations include dose and duration of precipitant drug administration, washout period between treatments, and whether the potential interaction that results will affect the pharmacokinetic assessment plan. Existing information available for the test agents should be reviewed to formulate expected outcomes. The expected outcomes should be considered to ensure that the proper pharmacokinetic and sometimes pharmacodynamic information is collected for all treatments. All drug-drug interaction studies should be planned to incorporate equivalence testing and to present mean ratio of treatment/reference and corresponding 90% confidence intervals. The “no-effect” bounds, typically 80.00–125.00%, should be stated in the plan and based on consideration of the therapeutic index and pharmacokinetic variability of the object drug.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ekins S (1996) Past, present, and future applications of precision-cut liver slices for in vitro xenobiotic metabolism. Drug Metab Rev 28(4):591–623
Decker CJ, Laitinen LM, Bridson GW et al (1998) Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 87(7):803–807
Bonnabry P, Sievering J, Leemann T et al (2001) Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studies. Clin Pharmacokinet 40(9):631–640
Rodrigues AD, Wong SL (1997) Application of human liver microsomes in metabolism-based drug-drug interactions: in vitro-in vivo correlations and the Abbott Laboratories experience. Adv Pharmacol 43:65–101
Koudriakova T, Iatsimirskaia E, Utkin I et al (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26(6):552–561
Hochman JH, Yamazaki M, Ohe T et al (2002) Evaluation of drug interactions with p-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with p-glycoprotein. Curr Drug Metab 3(3):257–273
Benet LZ, Cummins CL, Wu CY (2003) Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 4(5):393–398
Rolan PE (1994) Plasma protein binding displacement interactions--why are they still regarded as clinically important? Br J Clin Pharmacol 37(2):125–128
Sansom LN, Evans AM (1995) What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf 12(4):227–233
FDA US (2012) Guidance for industry: drug interaction studies – study design, data analysis, implications for dosing and labeling recommendations; draft guidance. February 2012, Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 1–79
EMA (2012) Guideline on the investigation of drug interactions. Committee for Human Medicinal Products, European Medicines Agency, June 21, 1–59
Bjornsson TD, Callaghan JT, Einolf HJ et al (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PHARMA) perspective. Drug Metab Dispos 31(7):815–832
Gallicano KD, Sahai J, Shukla VK et al (1999) Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol 48(2):168–179
Ormsby E (1994) Statistical methods in bioequivalence. CRC Press, Boca Raton
Wang BS, Wang XJ, Gong LK (2009) The construction of a williams design and randomization in cross-over clinical trials using SAS. J Stat Softw 29(1):1–10
Fleiss JL (1989) A critique of recent research on the two-treatment crossover design. Control Clin Trials 10(3):237–243
Vuorinen J (1997) A practical approach for the assessment of bioequivalence under selected higher-order cross-over designs. Stat Med 16(19):2229–2243
Chow SC, Liu JP (1992) On assessment of bioequivalence under a higher-order crossover design. J Biopharm Stat 2(2):239–256
Nix DE, Di Cicco RA, Miller AK et al (1999) The effect of low-dose cimetidine (200 mg twice daily) on the pharmacokinetics of theophylline. J Clin Pharmacol 39(8):855–865
Grasela TH Jr, Antal EJ, Ereshefsky L et al (1987) An evaluation of population pharmacokinetics in therapeutic trials. Part ii. Detection of a drug-drug interaction. Clini Pharmacol Ther 42(4):433–441
Purkins L, Wood N, Kleinermans D et al (2003) No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers. Br J Clin Pharmacol 56(Suppl 1):62–68
Cato A 3rd, Cavanaugh J, Shi H et al (1998) The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clini Pharmacol Ther 63(4):414–421
Romero AJ, Le Pogamp P, Nilsson LG et al (2002) Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clini Pharmacol Ther 71(4):226–234
Cadieux RJ (1989) Drug interactions in the elderly. How multiple drug use increases risk exponentially. Postgrad Med 86(8):179–186
Ragueneau I, Poirier JM, Radembino N et al (1999) Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers. Br J Clin Pharmacol 48(3):453–456
Piscitelli SC, Goss TF, Wilton JH et al (1991) Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother 35(9):1765–1771
Blum RA, D’Andrea DT, Florentino BM et al (1991) Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 114(9):755–757
Lebsack ME, Nix D, Ryerson B et al (1992) Effect of gastric acidity on enoxacin absorption. Clini Pharmacol Ther 52(3):252–256
Lehto P, Kivisto KT, Neuvonen PJ (1994) The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin. Br J Clin Pharmacol 37(1):82–85
Nix DE, Watson WA, Lener ME et al (1989) Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 46(6):700–705
Parpia SH, Nix DE, Hejmanowski LG et al (1989) Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother 33(1):99–102
Muller J, Keiser M, Drozdzik M et al (2017) Expression, regulation and function of intestinal drug transporters: an update. Biol Chem 398(2):175–192
Arakawa H, Kamioka H, Kanagawa M et al (2016) Possible interaction of quinolone antibiotics with peptide transporter 1 in oral absorption of peptide-mimetic drugs. Biopharm Drug Dispos 37(1):39–45
Shugarts S, Benet LZ (2009) The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 26(9):2039–2054
Misaka S, Miyazaki N, Yatabe MS et al (2013) Pharmacokinetic and pharmacodynamic interaction of nadolol with itraconazole, rifampicin and grapefruit juice in healthy volunteers. J Clin Pharmacol 53(7):738–745
Momper JD, Tsunoda SM, Ma JD (2016) Evaluation of proposed in vivo probe substrates and inhibitors for phenotyping transporter activity in humans. J Clin Pharmacol 56(Suppl 7):S82–S98
Jungbluth GL, Pasko MT, Beam TR et al (1989) Ceftriaxone disposition in open-heart surgery patients. Antimicrob Agents Chemother 33(6):850–856
Yin J, Wang J (2016) Renal drug transporters and their significance in drug-drug interactions. Acta Pharm Sin B 6(5):363–373
Ivanyuk A, Livio F, Biollaz J et al (2017) Renal drug transporters and drug interactions. Clin Pharmacokinet 56(8):825–892
Ebner T, Ishiguro N, Taub ME (2015) The use of transporter probe drug cocktails for the assessment of transporter-based drug-drug interactions in a clinical setting-proposal of a four component transporter cocktail. J Pharm Sci 104(9):3220–3228
Hagos Y, Wolff NA (2010) Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity. Toxins 2(8):2055–2082
Hsu V, de LT Vieira M, Zhao P et al (2014) Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. Clin Pharmacokinet 53(3):283–293
Rengelshausen J, Goggelmann C, Burhenne J et al (2003) Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol 56(1):32–38
Megran DW, Lefebvre K, Willetts V et al (1990) Single-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhea in men. Antimicrob Agents Chemother 34(2):355–357
Gaspari F, Perico N, Remuzzi G (1997) Measurement of glomerular filtration rate. Kidney Int Suppl 63:S151–S154
Brochner-Mortensen J (1985) Current status on assessment and measurement of glomerular filtration rate. Clin Physiol 5(1):1–17
Hellerstein S, Erwin P, Warady BA (2003) The cimetidine protocol: a convenient, accurate, and inexpensive way to measure glomerular filtration rate. Pediatr Nephrol 18(1):71–72
Baciewicz AM, Chrisman CR, Finch CK et al (2008) Update on rifampin and rifabutin drug interactions. Am J Med Sci 335(2):126–136
Wandel C, Bocker R, Bohrer H et al (1994) Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br J Anaesth 73(5):658–661
Thummel KE, Shen DD, Podoll TD et al (1994) Use of midazolam as a human cytochrome P450 3A probe: ii. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271(1):557–566
Lown KS, Thummel KE, Benedict PE et al (1995) The erythromycin breath test predicts the clearance of midazolam. Clini Pharmacol Ther 57(1):16–24
Watkins PB, Turgeon DK, Saenger P et al (1992) Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450iiiA (CYP3A) activity. Clini Pharmacol Ther 52(3):265–273
Hunt CM, Watkins PB, Saenger P et al (1992) Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clini Pharmacol Ther 51(1):18–23
Chiou WL, Jeong HY, Wu TC et al (2001) Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization. Clini Pharmacol Ther 70(4):305–310
Sarkar MA, Jackson BJ (1994) Theophylline N-demethylations as probes for P4501A1 and P4501A2. Drug Metab Dispos 22(6):827–834
Ziebell J, Shaw-Stiffel T (1995) Update on the use of metabolic probes to quantify liver function: caffeine versus lidocaine. Dig Dis 13(4):239–250
Anthony LB, Boeve TJ, Hande KR (1995) Cytochrome P-450iiD6 phenotyping in cancer patients: debrisoquin and dextromethorphan as probes. Cancer Chemother Pharmacol 36(2):125–128
Desta Z, Zhao X, Shin JG et al (2002) Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41(12):913–958
Fuhr U, Rost KL, Engelhardt R et al (1996) Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 6(2):159–176
Brockmoller J, Rost KL, Gross D et al (1995) Phenotyping of CYP2C19 with enantiospecific hplc-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 g-->a-splice site mutation. Pharmacogenetics 5(2):80–88
Guengerich FP (1997) Role of cytochrome p450 enzymes in drug-drug interactions. Adv Pharmacol 43:7–35
Tanaka E (1998) Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J Clinical Pharmacy Ther 23(6):403–416
Lomaestro BM, Piatek MA (1998) Update on drug interactions with azole antifungal agents. Ann Pharmacother 32(9):915–928
Caraco Y (1998) Genetic determinants of drug responsiveness and drug interactions. Ther Drug Monit 20(5):517–524
Shannon M (1997) Drug-drug interactions and the cytochrome P450 system: an update. Pediatr Emerg Care 13(5):350–353
Bradford PA, Sanders CC (1993) Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam. Antimicrob Agents Chemother 37(12):2578–2583
Mikus G, Schowel V, Drzewinska M et al (2006) Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clini Pharmacol Ther 80(2):126–135
Isoherranen N, Ludington SR, Givens RC et al (2008) The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab Dispos 36(1):146–154
Li D, Abudula A, Abulahake M et al (2010) Influence of CYP3A5 and MDR1 genetic polymorphisms on urinary 6 beta-hydroxycortisol/cortisol ratio after grapefruit juice intake in healthy Chinese. J Clin Pharmacol 50(7):775–784
Cho JY, Yu KS, Jang IJ et al (2002) Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic em genotype for CYP2C19. Br J Clin Pharmacol 53(4):393–397
Miura M, Inoue K, Kagaya H et al (2007) Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm Drug Dispos 28(4):167–175
Furuta T, Ohashi K, Kobayashi K et al (1999) Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clini Pharmacol Ther 66(3):265–274
Bramness JG, Skurtveit S, Gulliksen M et al (2005) The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects. Eur J Clin Pharmacol 61(7):499–506
Dumond JB, Vourvahis M, Rezk NL et al (2010) A phenotype-genotype approach to predicting CYP450 and p-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clinical Pharmacol Ther 87(6):735–742
Zachariasen RD (1994) Loss of oral contraceptive efficacy by concurrent antibiotic administration. Women Health 22(1):17–26
Suzuki E, Nakai D, Ikenaga H et al (2016) In vivo inhibition of acylpeptide hydrolase by carbapenem antibiotics causes the decrease of plasma concentration of valproic acid in dogs. Xenobiotica 46(2):126–131
Nguyen VX, Nix DE, Gillikin S et al (1989) Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. Antimicrob Agents Chemother 33(4):434–436
Neuvonen PJ, Penttila O (1974) Effect of oral ferrous sulphate on the half-life of doxycycline in man. Eur J Clin Pharmacol 7(5):361–363
Muller HJ, Gundert-Remy U (1994) The regulatory view on drug-drug interactions. Int J Clin Pharmacol Ther 32(6):269–273
Waller PC, Jackson PR, Tucker GT et al (1994) Clinical pharmacology with confidence. Br J Clin Pharmacol 37(4):309–310
Fuhr U, Weiss M, Kroemer HK et al (1996) Systematic screening for pharmacokinetic interactions during drug development. Int J Clin Pharmacol Ther 34(4):139–151
Kuhlmann J (1994) Drug interaction studies during drug development: which, when, how? Int J Clin Pharmacol Ther 32(6):305–311
Pidgen AW (1992) Statistical aspects of bioequivalence--a review. Xenobiotica 22(7):881–893
Steinijans VW, Hartmann M, Huber R et al (1996) Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther 34(1 Suppl):S25–S30
Gallicano K, Sahai J, Swick L et al (1995) Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. Clin Infect Dis 21(4):1008–1011
De Wit S, Debier M, De Smet M et al (1998) Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 42(2):223–227
Hauschke D, Kieser M, Diletti E et al (1999) Sample size determination for proving equivalence based on the ratio of two means for normally distributed data. Stat Med 18(1):93–105
Huang SM, Lesko LJ, Williams RL (1999) Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues. J Clin Pharmacol 39(10):1006–1014
Chow S, Liu JP (2000) Design and analysis of bioavailabilty and bioequivalence studies, second edition, revised and expanded. Marcel Dekker, New York
Wijnand H (1996) Some nonparametric confidence intervals are non-informative, notably in bioequivalence studies. Clin Res Reg Affairs 13:65–75
Midha KK, Ormsby ED, Hubbard JW et al (1993) Logarithmic transformation in bioequivalence: application with two formulations of perphenazine[erratum appears in j pharm sci 1993 dec;82(12):1300]. J Pharm Sci 82(2):138–144
Roe DJ, Karol MD (1997) Averaging pharmacokinetic parameter estimates from experimental studies: statistical theory and application. J Pharm Sci 86(5):621–624
Zintzaras E (2000) The existence of sequence effect in cross-over bioequivalence trials. Eur J Drug Metab Pharmacokinet 25(3–4):241–244
Hauschke D, Steinijans WV, Diletti E et al (1994) Presentation of the intrasubject coefficient of variation for sample size planning in bioequivalence studies. Int J Clin Pharmacol Ther 32(7):376–378
Steinijans VW, Sauter R, Hauschke D et al (1995) Reference tables for the intrasubject coefficient of variation in bioequivalence studies. Int J Clin Pharmacol Ther 33(8):427–430
Diletti E, Hauschke D, Steinijans VW (1992) Sample size determination: extended tables for the multiplicative model and bioequivalence ranges of 0.9 to 1.11 and 0.7 to 1.43. Int J Clini Pharmacol, Ther Toxicol 30(Suppl 1):S59–S62
Hauschke D, Steinijans VW, Diletti E et al (1992) Sample size determination for bioequivalence assessment using a multiplicative model. J Pharmacokinet Biopharm 20(5):557–561
Liu JP, Chow SC (1992) Sample size determination for the two one-sided tests procedure in bioequivalence. J Pharmacokinet Biopharm 20(1):101–104
Chow SC, Wang H (2001) On sample size calculation in bioequivalence trials.[erratum appears in j pharmacokinet pharmacodyn. 2002 feb;29(1):101]. J Pharmacokinet Pharmacodyn 28(2):155–169
Gallicano K, Sahai J, Zaror-Behrens G et al (1994) Effect of antacids in didanosine tablet on bioavailability of isoniazid. Antimicrob Agents Chemother 38(4):894–897
Schall R, Hundt HK, Luus HG (1994) Pharmacokinetic characteristics for extent of absorption and clearance in drug/drug interaction studies. Int J Clin Pharmacol Ther 32(12):633–637
Tozer TN, Bois FY, Hauck WW et al (1996) Absorption rate vs. exposure: which is more useful for bioequivalence testing? Pharm Res 13(3):453–456
van Giersbergen PL, Halabi A, Dingemanse J (2002) Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 53(6):589–595
Sanchez Garcia P, Paty I, Leister CA et al (2000) Effect of zaleplon on digoxin pharmacokinetics and pharmacodynamics. Am J Health Syst Pharm 57(24):2267–2270
Depre M, Van Hecken A, Verbesselt R et al (1999) Effect of multiple doses of montelukast, a cyslt1 receptor antagonist, on digoxin pharmacokinetics in healthy volunteers. J Clin Pharmacol 39(9):941–944
Dilger K, Zheng Z, Klotz U (1999) Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline. Br J Clin Pharmacol 48(3):438–444
Auclair B, Nix DE, Adam RD et al (2001) Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids. Antimicrob Agents Chemother 45(3):810–814
Damle BD, Mummaneni V, Kaul S et al (2002) Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. Antimicrob Agents Chemother 46(2):385–391
Banfield C, Herron J, Keung A et al (2002) Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet 41(Suppl 1):37–44
Hsu A, Granneman GR, Cao G et al (1998) Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 42(11):2784–2791
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Nix, D.E., Gallicano, K. (2018). Design and Data Analysis in Drug Interaction Studies. In: Pai, M., Kiser, J., Gubbins, P., Rodvold, K. (eds) Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions. Infectious Disease. Humana Press, Cham. https://doi.org/10.1007/978-3-319-72422-5_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-72422-5_9
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-72421-8
Online ISBN: 978-3-319-72422-5
eBook Packages: MedicineMedicine (R0)